Related Experiment Video

Updated: Apr 20, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

10.3K

Mechanisms that influence tumour response to VEGF-pathway inhibitors

Neil R Smith1, Stephen R Wedge2, Aurelien Pommier1

  • 1*Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.

Biochemical Society Transactions
|November 18, 2014
PubMed

Insights

Novel therapies targeting solid tumor vasculature show promise, but vascular endothelial growth factor (VEGF) inhibitors have limited efficacy. This review explores VEGF inhibitor successes, limitations, and future strategies for enhanced cancer treatment.

Area of Science:

  • Oncology
  • Vascular Biology
  • Pharmacology

Background:

  • Significant investment targets solid tumor vasculature via novel therapies.
  • Approaches aim to inhibit tumor angiogenesis or compromise existing tumor blood vessels.
  • Vascular endothelial growth factor (VEGF) signaling is a primary target, with approved therapeutics available.

Purpose of the Study:

  • To review clinical successes of VEGF inhibitors in solid tumors.
  • To identify factors limiting the utility of VEGF inhibitors.
  • To explore future opportunities for maximizing treatment benefits.

Main Methods:

  • Literature review of clinical studies on VEGF inhibitors.
  • Analysis of factors influencing VEGF inhibitor efficacy.
  • Discussion of potential strategies to enhance treatment outcomes.

Main Results:

  • VEGF inhibitors have demonstrated clinical success in treating solid tumors.
  • The widespread activity of VEGF inhibitors is not as extensive as initially predicted.
  • Several factors may limit the clinical utility and efficacy of these agents.

Conclusions:

  • Despite successes, VEGF inhibitors face limitations in broad clinical activity.
  • Understanding these limitations is crucial for improving cancer therapy.
  • Future research should focus on strategies to maximize the benefits of VEGF-targeted treatments.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

110

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K